Pregnancy upcoming surgery etcSome health conditions may make you more susceptible to the side-effects of the drug. Consult the full prescribing information for DESCOVY for more information on potentially significant drug interactions including clinical comments.
Descovy Healthcare Professional Web Site From Gilead
07162012 Most Recent Approval.
Descovy package insert. Department of Health and Human Services. TRUVADA emtricitabinetenofovir disoproxil fumarate. DESCOVY used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use.
Take as directed by your doctor or follow the. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Descovy is indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis PrEP to reduce the risk of HIV-1 infection from sexual acquisition excluding individuals at risk from receptive vaginal sex.
April 4 2016. Do not initiate DESCOVY for HIV-1 PrEP if signs or. Vitamins herbal supplements etc allergies pre-existing diseases and current health conditions eg.
Drug-resistant HIV-1 variants have been identified with use of FTCTDF for HIV-1 PrEP following undetected acute HIV-1 infection. DESCOVY a component of BIKTARVY is indicated in combination with other antiretroviral ARV agents for the treatment of HIV-1 infection in patients weighing at least 35 kg. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OZEMPIC safely and effectively.
Individuals must have a negative HIV-1 test immediately prior to initiating Descovy for HIV-1 PrEP. Its a first-choice option for the treatment and prevention of HIV and is a newer version of the combination medication Truvada. A clinical practice guideline.
See full prescribing information. Pediatric Labeling Approval Date. Program Step Therapy Descovy emtricitabinetenofovir alafenamide Change Control 102019 New step therapy program that requires the use of Truvada before.
Centers for Disease Control and Prevention. Accessed August 8 2020. DESCOVY package insert.
Descovy was approved for HIV prevention pre-exposure prophylaxis or PrEP in October 2019. DESCOVY is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. Panel on Antiretroviral Guidelines for Adults and Adolescents.
See Descovy for PrEP page. DESCOVY is not indicated for use as pre-exposure prophylaxis PrEP to. Emtricitabine F 200 mg in combination with tenofovir alafenamide TAF 25 mg FTAF brand name Descovy These medications are approved to prevent HIV infection in adults and adolescents weighing at least 35 kg 77 lb as follows.
Descovy emtricitabine and tenofovir alafenamide oral tablets. See the individual drugs contained in Descovy. Drugs that inhibit P-gp can increase the concentrations of components of DESCOVY.
Preexposure prophylaxis for the prevention of HIV infection in the United States2017 update. DESCOVY is a two-drug fixed dose combination product containing 200 mg of emtricitabine FTC and 25 mg of tenofovir alafenamide TAF. Supplemental NDA 21-752.
Descovy emtricitabine tenofovir alafenamide Descovy is a combination medication containing two HIV antiretrovirals ARVs emtricitabine Emtriva and tenofovir AF Vemlidy. Before using Descovy Tablet inform your doctor about your current list of medications over the counter products eg. The recommended dosage of DESCOVY for treatment of HIV-1 is one tablet taken orally once daily with or without food in.
Emtriva but TAF is not available separately for HIV. DESCOVY FOR PrEP must be prescribed only to patients confirmed to be HIV negative immediately prior to initiation and at least every 3 months during use. Lactic acidosis and severe hepatomegaly with steatosis including fatal cases have been reported with the use of nucleoside analogs and other antiretrovirals.
Drugs that induce P-gp can decrease the concentrations of components of DESCOVY which may lead to loss of efficacy and development of. RISK OF DRUG RESISTANCE WITH USE OF DESCOVY FOR PrEP IN UNDIAGNOSED EARLY HIV-1 INFECTION and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B. See package insert for more complete information on.
CIMDUO is contraindicated in patients with a previous hypersensitivity reaction to any of the components contained in the formulation.
